The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: Just a sidestep?

Summary Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD). Retinol-binding pr...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsy research 2013-05, Vol.104 (3), p.285-288
Main Authors: Rauchenzauner, M, Laimer, M, Wiedmann, M, Tschoner, A, Salzmann, K, Sturm, W, Sandhofer, A, Walser, G, Luef, G, Ebenbichler, C.F
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anticonvulsants - pharmacology
Biological and medical sciences
Child
Diabetes Mellitus, Type 2 - metabolism
Drug toxicity and drugs side effects treatment
Fatty Liver - drug therapy
Female
GLP-1
Glucagon-Like Peptide 1 - metabolism
Glucose - metabolism
Homeostasis - drug effects
Humans
Insulin resistance
Insulin Resistance - physiology
Liver - metabolism
Male
Medical sciences
Middle Aged
Miscellaneous (drug allergy, mutagens, teratogens...)
Neurology
Non-alcoholic Fatty Liver Disease
Pharmacology. Drug treatments
RBP4
Retinol-Binding Proteins, Plasma - metabolism
Valproic Acid - therapeutic use
VPA
Weight
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Valproic acid (VPA), as one of the most widely prescribed antiepileptic drugs (AED) for many types of epilepsy in adults and children, is associated with weight gain, alteration of adipocytokine homeostasis, insulin resistance and Non-Alcoholic Fatty Liver Disease (NAFLD). Retinol-binding protein 4 (RBP4) and Glucagon-like peptide-1 (GLP-1) are considered as important new targets in modern type 2 diabetes mellitus therapy linked to insulin resistance, NAFLD and visceral obesity acting via peripheral or central mechanisms. We herein demonstrate the lack of an influence of VPA treatment on RBP4 and GLP-1 in otherwise healthy patients. In summary, the absence of any relationship with RBP4 and GLP-1 concentrations does not suggest a role of these novel insulin resistance parameters as potential regulators of glucose and fat metabolism during VPA-therapy.
ISSN:0920-1211
1872-6844
DOI:10.1016/j.eplepsyres.2012.10.004